Technology
Choose a subcategory:
Orchid Cellmark Inc. and Subsidiaries Condensed Consolidated Statements of Operations Three months and twelve months ended December 31, 2009 and 2008 ( In thousands, except per share data) ( Unaudited) Three months ended Years ended Decembe
To read the entire report visit: http:// www.investorsoup. com/lp/ EXAS See what investors say about EXAS at penny stock forum InvestorSoup. com is a small-cap research and investment commentary provider.
The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including uncertainties with respect to the fact that additional tri
In particular, the risks and uncertainties include, among other things: risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured; the risk that we will not achieve the anticipated benefits of
2009 Highlights Droxidopa:- Initiated Phase II trial of Droxidopa in fibromyalgia- Reported statistically significant reduction ( 87.5%) in the number of patients requiring early termination of hemodialysis sessions in Phase II trial of Dro
COMBIMATRIX CORPORATION CONSOLIDATED SUMMARY FINANCIAL INFORMATION ( In thousands, except share and per share information) ( Unaudited) CONSOLIDATED BALANCE SHEET INFORMATION: December December 31, 31, 2009 2008 Total cash, cash equivalents
Nabi Biopharmaceuticals CONSOLIDATED BALANCE SHEETS December 27, December 2008 26, ( as In thousands 2009 adjusted) ASSETS Current assets: Cash and cash equivalents $ 59,510 $ 106,438 Marketable securities 59,489 23,900 Receivables 6,690- P
CALGARY, Alberta, March 10, 2010 ( GLOBE NEWSWIRE)- Liberty Analytics Co., a leading provider of large, small- and micro-cap independent investment research, today initiated coverage on Cerus Corp..
Examples of such risks and uncertainties are: risks relating to the rigorous regulatory requirements required for approval of any drug or drug-device combination products that Discovery Labs may develop, including that: ( a) Discovery Labs
Financial Highlights CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three months ended Year ended December 31, December 30, ( In thousands of United States dollars, except per share information) 2009 2008 2009 2008 ( Unaudited) Revenues Ne
To read the entire report visit: http:// www.stockpreacher. com/n/ BIEL See what investors are saying about BIEL at penny stock forum StockPreacher. com is a small-cap research and investment commentary provider.
QLT Announces Phase II Clinical Trial Results and Development Plans for the Punctal Plug Delivery Sy
VANCOUVER, British Columbia, March 10, 2010 ( GLOBE NEWSWIRE)-- 90-Day Retention Rate of 81% for Latest Punctal Plug Prototype Device- No Dose Response Seen with Higher Doses in Phase II Clinical Studies- Expand Development Plans of the Pun